Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06572553
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-13
Brief Title:
Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD DME and RVO Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD DME and RVO Patients
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to learn if drug Faricimab works to treat nAMD DME or RVO in adults It will also learn about the safety of drug Faricimab The main questions it aims to answer are
Does drug Faricimab can improve the best-corrected visual acuity of participants What medical problems do participants have when inject drug Faricimab Participants will inject drug Faricimab every month for 3 months Visit the clinic once every 2 weeks for checkups
Does drug Faricimab can improve the best-corrected visual acuity of participants What medical problems do participants have when inject drug Faricimab Participants will inject drug Faricimab every month for 3 months Visit the clinic once every 2 weeks for checkups
Detailed Description:
Intravitreal anti-vascular endothelial growth factor VEGF therapies are used to treat retinal vascular diseases such as neovascular wet age-related macular degeneration nAMD diabetic macular edema DME and retinal vein occlusion RVO However the clinical effectiveness of such therapies is often suboptimal often resulting in poor treatment adherence due to the burden of frequent monitoring and injection therapy every 4-8 weeks Different approaches have been investigated to improve outcomes in such diseases including modification of dosing regimens to reduce treatment burden and continued research to identify new drug targets Angiopoietin-2 Ang-2 has been implicated in the pathogenesis of several retinal vascular diseases including nAMD and DME and has therefore been identified as a potential new target
Faricimab faricimab-svoa Vabysmo a bispecific antibody that inhibits both VEGF-A and Ang-2 was developed by RocheGenentech Dual-pathway inhibition may provide stronger and longer-lasting efficacy in the treatment of retinal vascular disease Faricimab is administered via intravitreal injection It is the first bispecific antibody designed for intraocular use In January 2022 faricimab was approved in the United States for the treatment of participants with nAMD or DME And in March 2024 faricimab began to be approved for use in the treatment of patients in our clinic
Therefore investigators collected participants who were injected with Faricimab in the clinic and conducted follow-up visits to evaluate the therapeutic efficacy and application prospect of Faricimab in the clinic
Faricimab faricimab-svoa Vabysmo a bispecific antibody that inhibits both VEGF-A and Ang-2 was developed by RocheGenentech Dual-pathway inhibition may provide stronger and longer-lasting efficacy in the treatment of retinal vascular disease Faricimab is administered via intravitreal injection It is the first bispecific antibody designed for intraocular use In January 2022 faricimab was approved in the United States for the treatment of participants with nAMD or DME And in March 2024 faricimab began to be approved for use in the treatment of patients in our clinic
Therefore investigators collected participants who were injected with Faricimab in the clinic and conducted follow-up visits to evaluate the therapeutic efficacy and application prospect of Faricimab in the clinic
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None